NextCure (NXTC) director receives grant of 2,340 stock options at $2.02

Rhea-AI Filing Summary

NextCure, Inc. director John G. Houston reported a grant of stock options representing 2,340 shares of common stock. These options have an exercise price of $2.0200 per share and expire on June 17, 2036.

The option vests in full on the earlier of June 18, 2027 and the date of NextCure’s 2027 Annual Meeting of Stockholders, making this a routine, compensation-related award rather than an open-market purchase or sale. Following this grant, Houston holds options for 2,340 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Houston John G

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,340	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 2,340 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 2,340 options Exercise price: $2.0200 per share Expiration date: June 17, 2036 +2 more

5 metrics

Option grant size 2,340 options Stock Option (Right to Buy) for common stock

Exercise price $2.0200 per share Strike price for the 2,340-share option grant

Expiration date June 17, 2036 Option term end date

Vesting date trigger June 18, 2027 Earlier of this date or 2027 Annual Meeting

Post-grant derivative holdings 2,340 options Total options held following this grant

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Annual Meeting of Stockholders, exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Annual Meeting of Stockholders financial

"earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders"

exercise price financial

"conversion_or_exercise_price: 2.0200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Houston John G

(Last) (First) (Middle)

C/O NEXTCURE, INC.

9000 VIRGINIA MANOR ROAD, SUITE 200

(Street)

BELTSVILLE MARYLAND 20705

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.02	06/18/2026		A		2,340		(1)	06/17/2036	Common Stock	2,340	$0	2,340	D

Explanation of Responses:

1. The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

	/s/ Steven P. Cobourn, as attorney-in-fact for John G. Houston	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did NextCure (NXTC) director John G. Houston report in this Form 4?

He reported receiving a grant of stock options for 2,340 shares of NextCure common stock. The award is a compensation-related grant, not an open-market trade, and reflects additional equity-based incentives tied to his role as a director.

What is the exercise price of John G. Houston’s NextCure (NXTC) stock options?

The stock options have an exercise price of $2.0200 per share. This means Houston can buy NextCure common stock at this fixed price once the options vest, regardless of the market price at that time, until the options expire.

When do John G. Houston’s NextCure (NXTC) stock options vest?

The options vest in full on the earlier of June 18, 2027 and the date of NextCure’s 2027 Annual Meeting of Stockholders. Vested options become exercisable, allowing Houston to purchase the underlying common shares at the set exercise price.

When do John G. Houston’s NextCure (NXTC) stock options expire?

The options expire on June 17, 2036, giving a long exercise window. After this date, any unexercised options lapse and can no longer be used to acquire NextCure common shares at the $2.0200 exercise price.

How many NextCure (NXTC) derivative securities does John G. Houston hold after this grant?

After the transaction, Houston holds options covering 2,340 shares of NextCure common stock. This figure reflects his direct derivative holdings reported in this Form 4, all tied to the single option grant described in the filing.